ClinicalTrials.gg

Program

SHR-1826

A development code. Also written as “SHR-1826;Adebrelimab;SHR-8068;Bevacizumab”, “Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection” and “HRS-7058 + SHR-1826”.

In Jiangsu HengRui Medicine's pipeline, c-Met ADC. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Nov 19, 20247 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine77 open or runningphase 2since Nov 19, 2024Oct 16, 2023Dec 2026phase 2 · NCT06844474
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-1826, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2023First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06094556 · 240 planned · China
  2. Nov 19, 2024Phase 2 study in Advanced Solid TumorsNCT06703177 · 876 planned · China
  3. Dec 24, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06754930 · 400 planned · China
  4. Feb 19, 2025Phase 2 study in NSCLCNCT06844474 · 300 planned · China
  5. Apr 1, 2025Phase 2 study in Advanced Malignant TumourNCT06915142 · 300 planned · China
  6. Mar 18, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07489716 · 90 planned · China
  7. Jul 10, 2026Phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645 · 180 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourNCT06915142
  2. Dec 2026Primary completion: phase 2 study in NSCLCNCT06844474
  3. Jun 30, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT06094556
  4. Dec 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06754930

TargetBeta

“c-Met ADC”the company's pipeline, read by Claude · source

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibrulebeijing-pearl-biotechnology-limited-liability-companyphase 39
glumetinibruleHaihe Biopharmaphase 38
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
pamvatamigruleBetta Pharmaceuticalsphase 25

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07704645Resectable Non-small Cell Lung Cancer · China2Not yet recruitingJun 2028180
NCT07489716Carcinoma, Non-Small-Cell Lung · China2RecruitingAug 202890
NCT06915142Advanced Malignant Tumour · China2RecruitingDec 2026300
NCT06844474NSCLC · China2RecruitingDec 2026300
NCT06754930Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 2027400
NCT06703177Advanced Solid Tumors · China2RecruitingJan 1, 2026876
NCT06094556Advanced Solid Tumors · China1RecruitingJun 30, 2027240

How it is read

Names in the registry

  • “SHR-1826”, 4 entries
  • “SHR-1826;Adebrelimab;SHR-8068;Bevacizumab”, 1 entry
  • “Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection”, 1 entry
  • “HRS-7058 + SHR-1826”, 1 entry
  • “HRS-7058 + SHR-1826 + SHR-1316”, 1 entry

Codes read as this program: SHR1826.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.